Unicycive CEO to present at Guggenheim healthcare conference

Unicycive Therapeutics said CEO Shalabh Gupta will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on Nov. 10 at 2:30 p.m. ET. The appearance gives investors another look at the kidney-disease biotech's pipeline and comes as the company highlights its presentation materials online.

Why it matters: - The conference appearance gives Unicycive Therapeutics a public platform in front of healthcare investors and industry attendees. - The presentation may help keep attention on the company's kidney-disease pipeline, including its lead and second investigational treatments. - Investors can access a live and archived webcast through the Unicycive website under Investors > Events and Presentations.

What happened: - Unicycive Therapeutics said Chief Executive Officer Shalabh Gupta, M.D., will present at the Guggenheim 3rd Annual Healthcare Innovation Conference. - The presentation is scheduled for Tuesday, Nov. 10, 2026, at 2:30 p.m. ET. - Unicycive Therapeutics is a biotechnology company focused on therapies for patients with kidney disease. - Unicycive Therapeutics is a B2i Digital Featured Company, with an in-depth profile available here.

The details: - Unicycive's lead investigational treatment is oxylanthanum carbonate, a phosphate-binding agent for hyperphosphatemia in patients with chronic kidney disease who are on dialysis. - The company's second investigational treatment is UNI-494, which is intended for conditions related to acute kidney injury. - UNI-494 has received orphan drug designation from the FDA for the prevention of delayed graft function in kidney transplant patients. - UNI-494 has completed a Phase 1 dose-ranging safety study in healthy volunteers. - The company directs investors to its website for the webcast and presentation materials. - Unicycive also points readers to Unicycive.com and its LinkedIn and X accounts for more information.

Between the lines: - The announcement is a standard investor-conference update, but these events often serve as a visibility check for smaller biotech companies. - The focus on both oxylanthanum carbonate and UNI-494 signals that Unicycive wants to keep multiple programs in front of the market. - The company is also using third-party and owned channels, including B2i Digital and its investor page, to widen distribution.

What's next: - Unicycive's presentation on Nov. 10 is the next scheduled milestone in the announcement. - Investors will likely look for updates on clinical progress, regulatory status and development timelines tied to the company's kidney-disease programs. - The webcast archive should remain available on the Unicycive investor site after the live event.